Biology of Blood and Marrow Transplantation
Volume 16, Issue 9 , Pages 1222-1230, September 2010

Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction

  • Catherine Matte-Martone

      Affiliations

    • Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut
    • Department of Medicine, Yale University School of Medicine, New Haven, Connecticut
  • ,
  • Xiajian Wang

      Affiliations

    • Institute of Immunology, Zhejiang University, Hangzhou, People's Republic of China
  • ,
  • Britt Anderson

      Affiliations

    • Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut
  • ,
  • Dhanpat Jain

      Affiliations

    • Department of Pathology, Yale University School of Medicine, New Haven, Connecticut
  • ,
  • Anthony J. Demetris

      Affiliations

    • Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
  • ,
  • Jennifer McNiff

      Affiliations

    • Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut
  • ,
  • Mark J. Shlomchik

      Affiliations

    • Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut
    • Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut
  • ,
  • Warren D. Shlomchik

      Affiliations

    • Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut
    • Department of Medicine, Yale University School of Medicine, New Haven, Connecticut
    • Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut
    • Corresponding Author InformationCorrespondence and reprint requests: Warren D. Shlomchik, MD, Medical Oncology and Immunobiology, Yale University of Medicine, P.O. Box 208032, New Haven, CT 06620.

Received 18 January 2010; accepted 16 March 2010. published online 24 March 2010.

Recipient antigen presenting cells (APCs) are required for CD8-mediated graft-versus-host disease (GVHD), and have an important and nonredundant role in CD4-mediated GVHD in mouse major histocompatibility complex-matched allogeneic bone marrow transplantation (alloBMT). However, the precise roles of specific recipient APCs—dendritic cells, macrophages, and B cells—are not well defined. If recipient B cells are important APCs they could be depleted with rituximab, an anti-CD20 monoclonal antibody. On the other hand, B cells can downregulate T cell responses, and consequently, B cell depletion could exacerbate GVHD. Patients with B cell lymphomas undergo allogeneic hematopoietic stem cell transplantation (alloSCT) and many are B-cell-deficient because of prior rituximab. We therefore studied the role of recipient B cells in major histocompatibility complex-matched murine models of CD8- and CD4-mediated GVHD by using recipients genetically deficient in B cells and with antibody-mediated depletion of host B cells. In both CD4- and CD8-dependent models, B cell-deficient recipients developed clinical and pathologic GVHD. However, although CD8-mediated GVHD was clinically less severe in hosts genetically deficient in B cells, it was unaffected in anti-CD20-treated recipients. These data indicate that recipient B cells are not important initiators of GVHD, and that efforts to prevent GVHD by APC depletion should focus on other APC subsets.

Key Words: GVHD, B cells, Antigen presenting cells, Graft-versus-host disease

 

 C.M., X.W., and B.A. contributed equally to this article.

 Financial disclosure: See Acknowledgments on page 1229.

PII: S1083-8791(10)00121-7

doi:10.1016/j.bbmt.2010.03.015

Biology of Blood and Marrow Transplantation
Volume 16, Issue 9 , Pages 1222-1230, September 2010